LIPG-Targeting Peptides Block HBV Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis B virus (HBV) treatments lack effective inhibitors for HBV infection pathways beyond the NTCP receptor, and the mechanisms of HBV entry into cells are not fully understood, leaving HBV free to infect cells that do not express NTCP.
Innovation Solution
Development of an anti-HBV agent that targets endothelial lipase (LIPG), a host factor identified as crucial for HBV infection, using LIPG-binding peptides to inhibit HBV attachment and entry into liver cells, either by binding to LIPG on the cell surface or delivering into liver cells to block intracellular HBV proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleotide analogue inhibitors (entecavir, adefovir, tenofovir) are used to inhibit reverse transcription, then viral replication is reduced, but HBV can still infect cells through alternative pathways not involving NTCP
Solution Approach 1:
The invention segments the anti-HBV treatment approach by targeting different stages of the viral lifecycle. Instead of relying solely on reverse transcription inhibition, it introduces LIPG inhibitors that block the entry phase, creating a multi-point intervention strategy that covers both entry and replication pathways
Solution Approach 2:
The invention identifies LIPG as an intermediary host factor that facilitates HBV entry into hepatocytes. By targeting this intermediary protein rather than the virus directly, the invention blocks viral entry through a host-mediated mechanism, complementing existing direct-acting antivirals
2Reliability
If NTCP is targeted as the specific receptor for HBV infection, then viral entry is inhibited, but HBV can still infect cells that do not express NTCP or use alternative entry mechanisms
Solution Approach 1:
The invention makes the anti-HBV strategy more universal by targeting LIPG, a host factor that appears to be involved in HBV entry across different cell types and independent of NTCP expression. This approach extends protection to cells that may not express NTCP or use alternative entry mechanisms
Solution Approach 2:
Instead of targeting the viral receptor (NTCP) as conventionally done, the invention inverts the approach by targeting a host factor (LIPG) that facilitates viral entry. This host-directed therapy complements virus-directed approaches and covers entry pathways that NTCP targeting misses
3Reliability
If LIPG-binding peptides are used to inhibit HBV entry, then HBV DNA and cccDNA levels are reduced, but the peptides require delivery into hepatocytes for optimal effect
Solution Approach 1:
The invention uses carrier molecules as intermediaries to deliver LIPG-binding peptides into hepatocytes. These carriers facilitate cellular uptake and intracellular delivery, overcoming the barrier of peptide cell penetration while maintaining the therapeutic effect on HBV replication
Solution Approach 2:
The invention employs a nested structure where LIPG-binding peptides are encapsulated within carrier molecules for delivery. The peptide is nested inside the carrier, which protects it during transport and enables its delivery into the target cells where it can exert its anti-HBV effect
Data Source
AI summary
An anti-HBV agent according to the present invention contains as an active ingredient a substance that binds to LIPG and inhibits the function(s) of LIPG. The inventors of the present application have found that LIPG is a factor playing an important role in HBV attachment and uptake, and functions as a cofactor that supports HBV entry into cells independently of NTCP, and also contributes to HBV proliferation in cells. T The LIPG-binding substance binds to LIPG on the surface of liver cells to inhibit HBV attachment and uptake into cells and, when delivered into liver cells, binds to intracellular LIPG to block any step(s) in the intracellular HBV proliferation process, thereby exerting an anti-HBV activity.